Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis
| Autor: | E Martín-Mola, T Cobo-Ibáñez |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
musculoskeletal diseases
Oncology medicine.medical_specialty Arthritis Receptors Tumor Necrosis Factor Etanercept Arthritis Rheumatoid Psoriatic arthritis Double-Blind Method immune system diseases Internal medicine medicine Humans Pharmacology (medical) skin and connective tissue diseases Randomized Controlled Trials as Topic Pharmacology Ankylosing spondylitis business.industry General Medicine medicine.disease Clinical trial stomatognathic diseases Antirheumatic Agents Immunoglobulin G Rheumatoid arthritis Physical therapy Methotrexate Tumor necrosis factor alpha business medicine.drug |
| Zdroj: | Expert Opinion on Pharmacotherapy. 8:1373-1397 |
| ISSN: | 1744-7666 1465-6566 |
| DOI: | 10.1517/14656566.8.9.1373 |
| Popis: | Etanercept is a dimeric fusion protein based on the p75 TNF-alpha receptor. It binds to TNF-alpha and blocks its biologic activity. In randomized, double-blind, placebo-controlled trials, etanercept has therapeutic activity in rheumatoid arthritis, psoriatic arthritis, polyarticular-course juvenile idiopathic arthritis and ankylosing spondylitis. Etanercept improves joint inflammation, physical function and slows/halts structural damage, especially when combined with methotrexate. A sustained response is observed in a substantial percentage of patients. Although some safety issues should be considered before starting etanercept treatment, in general terms, etanercept is a well tolerated drug with an acceptable safety profile. The use of any TNF-alpha antagonist must be in agreement with the National Recommendations for Biologic Therapy, and in difficult clinical situations, a balance between risk/benefit needs to be obtained. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|